Phase i clinical trial of 4-1BB-based adoptive T-cell therapy for Epstein-Barr virus (EBV)-positive tumors

Journal of Immunotherapy

Volumn 39, Issue 3, 2016, Pages 140-148

  Eom, Hyeon Seok ^a   Choi, Beom K ^b   Lee, Youngjoo ^a   Lee, Hyewon ^a   Yun, Tak ^a   Kim, Young H ^a   Lee, Je Jung ^c   Kwon, Byoung S ^b,d  

^a National Cancer Center   (South Korea)

^b Cancer Immunology Branch   (South Korea)

^c Chonnam National University Medical School   (South Korea)

^d TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

4 1BB (CD137); Adoptive therapy; CD8+ T cells; EBViNT; IFN g

Indexed keywords

CD137 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HLA A2 ANTIGEN; HLA A24 ANTIGEN; LATENT MEMBRANE PROTEIN 2; LATENT MEMBRANE PROTEIN 2A; UNCLASSIFIED DRUG; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; EPITOPE; MATRIX PROTEIN; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INDUCED NATURAL T CELL; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LARGE CELL LYMPHOMA; MALE; MIDDLE AGED; NASOPHARYNX CARCINOMA; NK T CELL LYMPHOMA; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; T LYMPHOCYTE; BIOLOGICAL THERAPY; CANCER STAGING; COMPLICATION; EPSTEIN BARR VIRUS INFECTION; GENETICS; IMMUNOLOGY; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VIROLOGY; X-RAY COMPUTED TOMOGRAPHY;

AGED; ANTIGENS, CD137; CD8-POSITIVE T-LYMPHOCYTES; CELL- AND TISSUE-BASED THERAPY; COMBINED MODALITY THERAPY; EPITOPES, T-LYMPHOCYTE; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VIRAL MATRIX PROTEINS;

EID: 84960154522     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000113     Document Type: Article

References (24)

1. Gottschalk S, Heslop HE, Roon CM. Treatment of EpsteinBarr virus-associated malignancies with specific T cells. Adv Cancer Res. 2002;84:175-201.
2. Henie G, Henle W, Horwitz CA. Antibodies to Epstein-Barr virus-associated nuclear antigen in infectious mononucleosis. J Infect Dis. 1974;130:231-239.
3. Fukayama M, Hino R, Uozaki H. Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma. Cancer Sci. 2008;99:1726-1733.
4. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res. 2004;10:803-821.
5. Heslop HE, Brenner MK, Rooney C, et al. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther. 1994;5:381-397.
6. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med. 1994;331: 679-680.
7. Roskrow MA, Suzuki N, Gan Y, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 1998;91:2925-2934.
8. Bollard CM, Cooper LJ, Heslop HE. Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Best Pract Res Clin Haematol. 2008;21:405-420.
9. Cannons JL, Lau P, Ghumman B, et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol. 2001;167:1313-1324.
10. Pollok KE, Kim YJ, Zhou Z, et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol. 1993;150:771-781.
11. Choi BK, Lee SC, Lee MJ, et al. 4-1BB-based isolation and expansion of CD8+ T cells specific for self-tumor and non-self-tumor antigens for adoptive T-cell therapy. J Immunother. 2014;37:225-236.
12. Kennedy-Nasser AA, Bollard CM, Heslop HE. Immunotherapy for epstein-barr virus-related lymphomas. Mediterr J Hematol Infect Dis. 2009;1:e2009010.
13. Murray PG, Young LS. The role of the Epstein-Barr virus in human disease. Front Biosci. 2002;7:d519-d540.
14. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25: 579-586.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
16. Simon R, Freidlin B, Rubinstein L, et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst. 1997;89:1138-1147.
17. Comoli P, Pedrazzoli P, Maccario R, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol. 2005;23: 8942-8949.
18. Straathof KC, Bollard CM, Popat U, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood. 2005;105:1898-1904.
19. Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004;200:1623-1633.
20. Louis CU, Straathof K, Bollard CM, et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009;113:2442-2450.
21. Disis ML, Wallace DR, Gooley TA, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol. 2009;27:4685-4692.
22. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 2007;117:1466-1476.
23. Vignard V, Lemercier B, Lim A, et al. Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J Immunol. 2005;175:4797-4805.
24. Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013; 19:747-752.